Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ABEO's Cash-to-Debt is ranked higher than
98% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ABEO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ABEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.12 Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ABEO's Equity-to-Asset is ranked higher than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ABEO: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ABEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -118.34  Med: -0.27 Max: 0.92
Current: 0.92
-118.34
0.92
Piotroski F-Score: 3
Altman Z-Score: 49.73
Beneish M-Score: -2.71
WACC vs ROIC
17.20%
-80.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2933.57
ABEO's Operating Margin % is ranked lower than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ABEO: -2933.57 )
Ranked among companies with meaningful Operating Margin % only.
ABEO' s Operating Margin % Range Over the Past 10 Years
Min: -12105.26  Med: -1697.98 Max: -98
Current: -2933.57
-12105.26
-98
Net Margin % -2746.38
ABEO's Net Margin % is ranked lower than
86% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ABEO: -2746.38 )
Ranked among companies with meaningful Net Margin % only.
ABEO' s Net Margin % Range Over the Past 10 Years
Min: -38147.37  Med: -2013.67 Max: 217.87
Current: -2746.38
-38147.37
217.87
ROE % -28.31
ABEO's ROE % is ranked higher than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ABEO: -28.31 )
Ranked among companies with meaningful ROE % only.
ABEO' s ROE % Range Over the Past 10 Years
Min: -40.05  Med: -33.14 Max: -26.22
Current: -28.31
-40.05
-26.22
ROA % -25.11
ABEO's ROA % is ranked higher than
54% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ABEO: -25.11 )
Ranked among companies with meaningful ROA % only.
ABEO' s ROA % Range Over the Past 10 Years
Min: -602.71  Med: -212.41 Max: 379.77
Current: -25.11
-602.71
379.77
ROC (Joel Greenblatt) % -3246.00
ABEO's ROC (Joel Greenblatt) % is ranked lower than
76% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ABEO: -3246.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ABEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -523920  Med: -12054.1 Max: 72738.46
Current: -3246
-523920
72738.46
3-Year Revenue Growth Rate -81.40
ABEO's 3-Year Revenue Growth Rate is ranked lower than
91% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ABEO: -81.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ABEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -81.4 Max: 198.1
Current: -81.4
0
198.1
GuruFocus has detected 6 Warning Signs with Abeona Therapeutics Inc $ABEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABEO's 30-Y Financials

Financials (Next Earnings Date: 2017-11-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ABEO Guru Trades in Q3 2016

George Soros 1,462,122 sh (unchged)
Chuck Royce 374,821 sh (-0.40%)
» More
Q4 2016

ABEO Guru Trades in Q4 2016

Paul Tudor Jones 33,500 sh (New)
Chuck Royce 312,221 sh (-16.70%)
George Soros 896,642 sh (-38.68%)
» More
Q1 2017

ABEO Guru Trades in Q1 2017

Louis Moore Bacon 150,000 sh (New)
Paul Tudor Jones 33,500 sh (unchged)
Chuck Royce 312,221 sh (unchged)
George Soros 896,642 sh (unchged)
» More
Q2 2017

ABEO Guru Trades in Q2 2017

George Soros 896,642 sh (unchged)
Chuck Royce 312,221 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon 100,000 sh (-33.33%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ABEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2016-12-31 Reduce -38.68%0.12%$4.25 - $8.7 $ 16.75168%896,642
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325413    SIC: 2834
Compare:NAS:AMAG, NAS:BOLD, NAS:ALDR, NAS:ACRS, NAS:AKAO, NAS:LJPC, NAS:PRTK, NAS:DOVA, NAS:INSY, NAS:CHRS, NAS:RXDX, NAS:GTHX, NAS:VSAR, NAS:ANAB, NAS:MGNX, NAS:CTMX, NAS:RVNC, NAS:CYTK, NAS:IMGN, NAS:KALA » details
Traded in other countries:PCJP.Germany,
Headquarter Location:USA
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB.

Ratios

vs
industry
vs
history
PB Ratio 7.58
ABEO's PB Ratio is ranked higher than
66% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ABEO: 7.58 )
Ranked among companies with meaningful PB Ratio only.
ABEO' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.45 Max: 55.44
Current: 7.58
1.16
55.44
PS Ratio 728.27
ABEO's PS Ratio is ranked lower than
92% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ABEO: 728.27 )
Ranked among companies with meaningful PS Ratio only.
ABEO' s PS Ratio Range Over the Past 10 Years
Min: 1.27  Med: 63.4 Max: 2740.96
Current: 728.27
1.27
2740.96
EV-to-EBIT -26.62
ABEO's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ABEO: -26.62 )
Ranked among companies with meaningful EV-to-EBIT only.
ABEO' s EV-to-EBIT Range Over the Past 10 Years
Min: -112.3  Med: -4.2 Max: 2
Current: -26.62
-112.3
2
EV-to-EBITDA -27.76
ABEO's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ABEO: -27.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABEO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -114.8  Med: -4.3 Max: 2
Current: -27.76
-114.8
2
EV-to-Revenue 731.35
ABEO's EV-to-Revenue is ranked lower than
88% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ABEO: 731.35 )
Ranked among companies with meaningful EV-to-Revenue only.
ABEO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 71.3 Max: 5351.7
Current: 731.35
1.2
5351.7
Current Ratio 14.05
ABEO's Current Ratio is ranked higher than
81% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ABEO: 14.05 )
Ranked among companies with meaningful Current Ratio only.
ABEO' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.06 Max: 27.83
Current: 14.05
0.02
27.83
Quick Ratio 14.05
ABEO's Quick Ratio is ranked higher than
82% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ABEO: 14.05 )
Ranked among companies with meaningful Quick Ratio only.
ABEO' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.06 Max: 27.83
Current: 14.05
0.02
27.83
Days Sales Outstanding 42.00
ABEO's Days Sales Outstanding is ranked higher than
51% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ABEO: 42.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.23  Med: 58.5 Max: 6185.79
Current: 42
13.23
6185.79

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -328.90
ABEO's 3-Year Average Share Buyback Ratio is ranked lower than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ABEO: -328.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -328.9  Med: -11.9 Max: 0
Current: -328.9
-328.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.29
ABEO's Price-to-Net-Cash is ranked higher than
66% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ABEO: 13.29 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABEO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.28  Med: 6.08 Max: 110.58
Current: 13.29
3.28
110.58
Price-to-Net-Current-Asset-Value 13.09
ABEO's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ABEO: 13.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABEO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.2  Med: 5.42 Max: 119.9
Current: 13.09
3.2
119.9
Price-to-Tangible-Book 12.88
ABEO's Price-to-Tangible-Book is ranked higher than
51% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ABEO: 12.88 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABEO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 4.92 Max: 40
Current: 12.88
3.14
40
Price-to-Median-PS-Value 11.47
ABEO's Price-to-Median-PS-Value is ranked lower than
93% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ABEO: 11.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 1.19 Max: 899.28
Current: 11.47
0.02
899.28
Earnings Yield (Greenblatt) % -3.74
ABEO's Earnings Yield (Greenblatt) % is ranked lower than
58% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ABEO: -3.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -438.8  Med: -22 Max: 78.5
Current: -3.74
-438.8
78.5

More Statistics

Revenue (TTM) (Mil) $0.84
EPS (TTM) $ -0.61
Beta2.50
Short Percentage of Float27.97%
52-Week Range $4.05 - 17.25
Shares Outstanding (Mil)40.29

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 1 2 6 155
EPS ($) -0.68 -0.75 -0.69 1.89
EPS without NRI ($) -0.68 -0.75 -0.69 1.89
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ABEO

Headlines

Articles On GuruFocus.com
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy Aug 29 2017 
Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights Aug 15 2017 
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer Jul 25 2017 
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy f Jul 18 2017 
Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference Jun 02 2017 
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for May 30 2017 
Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patient May 25 2017 
Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights May 16 2017 
Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASG May 12 2017 
Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-10 May 09 2017 

More From Other Websites
ETFs with exposure to Abeona Therapeutics, Inc. : September 18, 2017 Sep 18 2017
RBC Capital's Marc Harris breaks down his best biotech pi... Sep 18 2017
Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher Sep 18 2017
How Should You Think About Abeona Therapeutics Inc’s (ABEO) Risks? Sep 15 2017
ETFs with exposure to Abeona Therapeutics, Inc. : August 31, 2017 Aug 31 2017
Biotechs On The Move Aug 31 2017
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy... Aug 29 2017
Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will... Aug 25 2017
Abeona Therapeutics, Inc. :ABEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
Edited Transcript of ABEO earnings conference call or presentation 22-Aug-17 2:00pm GMT Aug 23 2017
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 Aug 17 2017
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in... Aug 16 2017
Abeona Therapeutics reports 2Q loss Aug 15 2017
Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights Aug 15 2017
Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer Jul 25 2017
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy... Jul 18 2017
ETFs with exposure to Abeona Therapeutics, Inc. : July 10, 2017 Jul 10 2017
Ahead of this year's MLB All-Star Game, here are 4 home r... Jul 07 2017
Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% Jul 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}